未登录ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC)
Rugo, Hope; Bardia, Aditya; Cortes, Javier; Curigliano, Giuseppe; Hamilton, Erika; Hurvitz, Sara; Loibl, Sibylle; Scartoni, Simona; Sahmoud, Tarek; Grzegorzewski, Krzysztof; Habboubi, Nassir; O'Shaughnessy, Joyce .png)
分享.png)
收藏ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancerHamilton, Erika; Pusztai, Lajos; Soliman, Hatem H.; Hurvitz, Sara; Grzegorzewski, Krzysztof; Habboubi, Nassir; Marreddy, Priya; Sahmoud, Tarek; Ibrahim, Nuhad 分享 收藏 The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitorsKamaraju, Sailaja; Fowler, Amy; Chaudhary, Lubna N.; Burkard, Mark; Giever, Thomas; Hegeman, Robert N.; Pipp-Dahm, Michele; Cheng, Yee Chung; Lange, Carol; Jorns, Julie M.; Stella, Amy; Siddiqui, Nauman; Zurbriggen, Luke; Rajguru, Saurabh; Tarima, Sergey; Sriram, Deepika; Retseck, Janet; Rui, Hallgeir; Sahmoud, Tarek; Wisinski, Kari B. 分享 收藏 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic settingBardia, Aditya; Bidard, Francois-Clement; Neven, Patrick; Streich, Guillermo; Montero, Alberto J.; Forget, Frederic; Mouret-Reynier, Marie-Ange; Sohn, Joo Hyuk; Taylor, Donatienne; Harnden, Kathleen K.; Khong, Hung; Kocsis, Judit; Dalenc, Florence; Dillon, Patrick; Babu, Sunil; Waters, Simon; Deleu, Ines; Garcia-Saenz, Jose Angel; Bria, Emilio; Cazzaniga, Marina Elena; Aftimos, Philippe; Cortes, Javier; Tonini, Giulia; Sahmoud, Tarek; Habboubi, Nassir; Grzegorzewski, Krzysztof; Kaklamani, Virginia 分享 收藏 Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant for Breast CancerFurman, Craig; Puyang, Xiaoling; Zhang, Zhaojie; Wu, Zhenhua J.; Banka, Deepti; Aithal, Kiran B.; Albacker, Lee A.; Hao, Ming-Hong; Irwin, Sean; Kim, Amy; Montesion, Meagan; Moriarty, Alyssa D.; Murugesan, Karthikeyan; Nguyen, Tuong-Vi; Rimkunas, Victoria; Sahmoud, Tarek; Wick, Michael J.; Yao, Shihua; Zhang, Xun; Zeng, Hao; Vaillancourt, Frederic H.; Bolduc, David M.; Larsen, Nicholas; Zheng, Guo Zhu; Prajapati, Sudeep; Zhu, Ping; Korpal, Manav 分享 收藏 The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitorsKamaraju, Sailaja; Fowler, Amy; Cheng, Chung Yee; Chaudhary, Lubna N.; Burfeind, John; Retseck, Janet; Tevaarwerk, Amye J.; Burkard, Mark; Paplomata, Elisavet; Parkes, Amanda M.; Jorns, Julie M.; Tarima, Sergey; Yee, Douglas; Rui, Hallgeir; Lange, Carol; Sahmoud, Tarek; Wisinski, Kari B. 分享 收藏 H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b studyJohnston, Stephen; Pluard, Timothy J.; Wang, Judy S.; Hamilton, Erika P.; Juric, Dejan; Scholz, Catherine R.; Hnitecki, Elizabeth; Dar, Sara; Gao, Lei; Cantagallo, Lisa; Korpal, Manav; Xiao, Jianjun Alan; Yu, Lihua; Sahmoud, Tarek; Gualberto, Antonio 分享 收藏 H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II studyHamilton, Erika P.; Wang, Judy S.; Pluard, Timothy; Morikawa, Aki; Dees, E. Claire; Jones, Robert H.; Haley, Barbara; Armstrong, Anne; Cohen, Adam L.; Munster, Pamela; Wright, Gail S.; Kayali, Fadi; Cantagallo, Lisa; Korpal, Manav; Long, Jenny; Xiao, Jianjun; Destenaves, Benoit; Gao, Lei; Sahmoud, Tarek; Gualberto, Antonio; Juric, Dejan 分享 收藏 Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancerSmith, Peter G.; Puyang, Xiaoling; Furman, Craig; Zheng, Guo Zhu; Banka, Deepti; Thomas, Michael; Subramanian, Vanitha; Irwin, Sean; Larsen, Nicholas; Caleb, Benjamin; Karr, Craig; Wu, Jeremy; O'Shea, Morgan; Yang, Joyce; Davis, Allison; Kim, Amy; Rioux, Nathalie; Rimkunas, Victoria; Yao, Huilan; MacKenzie, Crystal; Kumar, Pavan; Smith, Sherri; Eckley, Sean; Hart, Andrew; Lai, George; Rowbottom, Christopher; Fekkes, Peter; Buonamici, Silvia; Reynolds, Dominic; Yu, Lihua; Sahmoud, Tarek; Warmuth, Markus; Mitchell, Lorna; Zhu, Ping; Korpal, Manav 分享 收藏 A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapyHurvitz, Sara A.; Dalenc, Florence; Campone, Mario; O'Regan, Ruth M.; Tjan-Heijnen, Vivianne C.; Gligorov, Joseph; Llombart, Antonio; Jhangiani, Haresh; Mirshahidi, Hamid R.; Tan-Chiu, Elizabeth; Miao, Sara; El-Hashimy, Mona; Lincy, Jeremie; Taran, Tetiana; Soria, Jean-Charles; Sahmoud, Tarek; Andre, Fabrice 分享 收藏 Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study内脏转移对依维莫司治疗绝经后晚期乳腺癌的疗效和安全性的影响: 来自BOLERO-2研究的亚组分析Campone, Mario; Bachelot, Thomas; Gnant, Michael; Deleu, Ines; Rugo, Hope S.; Pistilli, Barbara; Noguchi, Shinzaburo; Shtivelband, Mikhail; Pritchard, Kathleen I.; Provencher, Louise; Burris, Howard A., III; Hart, Lowell; Melichar, Bohuslav; Hortobagyi, Gabriel N.; Arena, Francis; Baselga, Jose; Panneerselvam, Ashok; Heniquez, Aurelia; El-Hashimyt, Mona; Taran, Tetiana; Sahmoud, Tarek; Piccart, Martine 分享 收藏 Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trialBaselga, Jose; Piccart, Martine; Rugo, Hope; Chen, David; Burris, Howard A.; Campone, Mario; Noguchi, Shinzaburo; Perez, Alejandra; Deleu, Inas; Shtivelband, Mikhail; Provencher, Louise; Derti, Adnan; Huang, Alan; McDonald, Rob; Kalfoglou, Creton; Robinson, Douglas; Taran, Tetiana; Sahmoud, Tarek; Lebwohl, David; Hortobagyi, Gabriel N. 分享 收藏 Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialBurris, Howard A., III; Lebrun, Fabienne; Rugo, Hope S.; Beck, J. Thaddeus; Piccart, Martine; Neven, Patrick; Baselga, Jose; Petrakova, Katarina; Hortobagyi, Gabriel N.; Komorowski, Anna; Chouinard, Edmond; Young, Robyn; Gnant, Michael; Pritchard, Kathleen I.; Bennett, Lee; Ricci, Jean-Francois; Bauly, Hounayda; Taran, Tetiana; Sahmoud, Tarek; Noguchi, Shinzaburo 分享 收藏 Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialBissler, John J.; Kingswood, J. Christopher; Radzikowska, Elzbieta; Zonnenberg, Bernard A.; Frost, Michael; Belousova, Elena; Sauter, Matthias; Nonomura, Norio; Brakemeier, Susanne; de Vries, Petrus J.; Whittemore, Vicky H.; Chen, David; Sahmoud, Tarek; Shah, Gaurav; Lincy, Jeremie; Lebwohl, David; Budde, Klemens 分享 收藏 Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2Gnant, Michael; Baselga, Jose; Rugo, Hope S.; Noguchi, Shinzaburo; Burris, Howard A.; Piccart, Martine; Hortobagyi, Gabriel N.; Eakle, Janice; Mukai, Hirofumi; Iwata, Hiroji; Geberth, Matthias; Hart, Lowell L.; Hadji, Peyman; El-Hashimy, Mona; Rao, Shantha; Taran, Tetiana; Sahmoud, Tarek; Lebwohl, David; Campone, Mario; Pritchard, Kathleen I. 分享 收藏 Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2Noguchi, Shinzaburo; Masuda, Norikazu; Iwata, Hiroji; Mukai, Hirofumi; Horiguchi, Jun; Puttawibul, Puttisak; Srimuninnimit, Vichien; Tokuda, Yutaka; Kuroi, Katsumasa; Iwase, Hirotaka; Inaji, Hideo; Ohsumi, Shozo; Noh, Woo-Chul; Nakayama, Takahiro; Ohno, Shinji; Rai, Yoshiaki; Park, Byeong-Woo; Panneerselvam, Ashok; El-Hashimy, Mona; Taran, Tetiana; Sahmoud, Tarek; Ito, Yoshinori 分享 收藏 Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialFranz, David Neal; Belousova, Elena; Sparagana, Steven; Bebin, E. Martina; Frost, Michael; Kuperman, Rachel; Witt, Olaf; Kohrman, Michael H.; Flamini, J. Robert; Wu, Joyce Y.; Curatolo, Paolo; de Vries, Petrus J.; Whittemore, Vicky H.; Thiele, Elizabeth A.; Ford, James P.; Shah, Gaurav; Cauwel, Helene; Lebwohl, David; Sahmoud, Tarek; Jozwiak, Sergiusz 分享 收藏 分享 收藏 EXIST-2: EFFECT OF EVEROLIMUS ON ANGIOMYOLIPOMA IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX OR SPORADIC LYMPHANGIOMYOMATOSISBissler, John; Kingswood, J. Chris; Zonnenberg, Bernard; Frost, Michael; Belousova, Elena; Radzikowska, Elzbieta; Fischereder, Michael; Nonomura, Norio; Brakemeier, Susanne; de Vries, Petrus J.; Sahmoud, Tarek; Shah, Gaurav; Miao, Sara; Gray, Diep; Budde, Klemens 分享 收藏 Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer依维莫司治疗绝经后激素受体阳性晚期乳腺癌Baselga, Jose; Campone, Mario; Piccart, Martine; Burris, Howard A., III; Rugo, Hope S.; Sahmoud, Tarek; Noguchi, Shinzaburo; Gnant, Michael; Pritchard, Kathleen I.; Lebrun, Fabienne; Beck, J. Thaddeus; Ito, Yoshinori; Yardley, Denise; Deleu, Ines; Perez, Alejandra; Bachelot, Thomas; Vittori, Luc; Xu, Zhiying; Mukhopadhyay, Pabak; Lebwohl, David; Hortobagyi, Gabriel N. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
